Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19991802 | 0.83 | THRB (0.41) | THRBTGFBR1KDM4EMAPK14CSNK1D | |
| SCHEMBL29049906 | 0.79 | TGFBR1 (0.55) | THRBTGFBR1MAPK14CSNK1D | |
| SCHEMBL2526666 | 0.78 | THRB (0.43) | THRBTGFBR1KDM4EMAPK14 | |
| SCHEMBL2522496 | 0.78 | CSNK1D (0.47) | THRBTGFBR1KDM4EMAPK14MAPT | |
| SCHEMBL14844873 | 0.76 | THRB (0.53) | THRBTGFBR1KDM4EMAPK14CSNK1D | |
| SCHEMBL14844957 | 0.75 | TGFBR1 (0.54) | THRBTGFBR1MAPK14CSNK1E | |
| SCHEMBL2561853 | 0.75 | CSNK1D (0.40) | THRBTGFBR1KDM4EMAPK14MAPT | |
| SCHEMBL3944132 | 0.73 | THRB (0.61) | THRBTGFBR1MAPK14 | |
| SCHEMBL18114976 | 0.72 | TGFBR1 (0.36) | THRBTGFBR1KDM4EMAPK14MAPT | |
| SCHEMBL412002 | 0.72 | TGFBR1 (0.71) | THRBTGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556073-B1 | BICYCLIC PYRIDINYL PYRAZOLES | BAYER IP GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8507472-B2 | Bicyclic pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-13 | — | — | US | disclosed |
| CN-102947303-A | Bicyclic pyrimidinyl pyrazoles | BAYER CROPSCIENCE AG | 2013-02-27 | — | — | CN | disclosed |
| EP-2556073-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124539-A1 | BICYCLIC PYRIMIDINYL PYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | THRB 3803/4885TGFBR1 2921/4885KDM4E 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.